Amyloidosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
* Cardiac biomarkers are the most important predictors of outcome in amyloidosis and provide a quantitative assessment for: | * Cardiac biomarkers are the most important predictors of outcome in amyloidosis and provide a quantitative assessment for:<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | ||
** Cardiac damage (Troponin I or Troponin T) | ** Cardiac damage (Troponin I or Troponin T) | ||
** Wall strain (BNP and NT-proBNP) | ** Wall strain (BNP and NT-proBNP) | ||
Revision as of 14:40, 3 May 2018
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Amyloidosis laboratory findings |
|
Risk calculators and risk factors for Amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
Laboratory Findings
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis and provide a quantitative assessment for:[1]
- Cardiac damage (Troponin I or Troponin T)
- Wall strain (BNP and NT-proBNP)
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.